ArticleFrontiers in microbiology2022
Orlistat and ezetimibe could differently alleviate the high-fat diet-induced obesity phenotype by modulating the gut microbiota.
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- The relationship between diabetic retinopathy and intestinal microbiota: a systematic review and meta analysis.International ophthalmology · 2026Pooled it
- Hypocholesterolemic agents and the gut microbiota: a review of interactions and modulatory activity.Pharmacological reports : PR · 2026Review
- Weight Loss-Associated Remodeling of Adipose Tissue Immunometabolism.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Review
- Curcumin alleviates visceral adiposity via inhibiting GIP release from hypoxic intestinal damage in MASH rats.NPJ science of food · 2025Article
- Orlistat ameliorates lipid dysmetabolism in high-fat diet-induced mice via gut microbiota modulation.Frontiers in microbiology · 2025Article
- Decoding electroacupuncture's efficacy: a comparative study on gut microbiota and metabolic profiles in C57 and 3xTg-AD mice.Frontiers in microbiology · 2025Article
- Effects of yeast culture (Frontiers in microbiology · 2025Article
- Interactions between gut microbiota and cardiovascular drugs: effects on drug therapeutic effect and side effect.Frontiers in cardiovascular medicine · 2025Review
- Association between lipid-lowering agents with intervertebral disc degeneration, sciatica and low back pain: a drug-targeted mendelian randomized study and cross-sectional observation.Lipids in health and disease · 2024Observational
- Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database.Heliyon · 2024Article
- Targeting the Gut Microbiome to Treat Cardiometabolic Disease.Current atherosclerosis reports · 2024Review
- An Analysis of the Gut Microbiota and Related Metabolites following PCSK9 Inhibition in Statin-Treated Patients with Elevated Levels of Lipoprotein(a).Microorganisms · 2024Article
- Association of lipid-lowering drugs with osteoarthritis outcomes from a drug-target Mendelian randomization study.PloS one · 2024Article
- Evaluation of gut microbiota alterations following orlistat administration in obese mice.Frontiers in endocrinology · 2024Article
- Gut microbiota and therapy for obesity and type 2 diabetes.Frontiers in endocrinology · 2024Review
- Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the ATFrontiers in pharmacology · 2024Article
- Dietary diosgenin transcriptionally down-regulated intestinal NPC1L1 expression to prevent cholesterol gallstone formation in mice.Journal of biomedical science · 2023Article
- The gut microbiota in obesity and weight management: microbes as friends or foe?Nature reviews. Endocrinology · 2023Review
- Intestinal flora: A new target for traditional Chinese medicine to improve lipid metabolism disorders.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the possible anti-obesity effects of orlistat and ezetimibe and determine the mechanism by which they alter the composition of gut microbiota and short-chain fatty acids (SCFAs) in mice with a high-fat diet (HFD)-induced obesity. Eighty male, specific pathogen-free C57BL/6J mice aged 3 weeks were divided into four groups (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.